CRL — Charles River Laboratories International, Inc.

Summary of Charles River Laboratories Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $996 million, a 1.2% increase year-over-year; organic revenue declined by 1.5%.
• Non-GAAP Operating Margin: 16.3%, down 280 basis points year-over-year.
• Earnings Per Share (EPS): $2.06, a 12% decline from the previous year.
• Net Book-to-Bill Ratio: 1.04x, indicating solid demand.
• Free Cash Flow: Negative $15 million, primarily due to higher performance-based cash bonuses.
• Net Interest Expense: $26 million, with an increased outlook for the full year to $103-$108 million.
• Unallocated Corporate Costs: $63 million, up from 5.3% to 6.4% of revenue.

2. Strategic Updates and Business Highlights

• Leadership Transition: Birgit Girshick has taken over as CEO, emphasizing a commitment to modernizing operations and enhancing shareholder value.
• Pathway to Purpose Strategy: A new strategic framework focusing on operational modernization, strengthening scientific capabilities, and enhancing client relationships.
• Acquisitions: Completed the acquisition of K.F. Cambodia and PathoQuest, enhancing non-human primate (NHP) supply and advancing new approach methodologies (NAMs).
• Divestitures: Successfully divested CDMO and Cell Solutions businesses, with plans to divest certain European discovery sites.
• Technology Investments: Continued focus on AI and digital tools to streamline operations and improve client engagement.

3. Forward Guidance and Outlook

• 2026 Guidance: Reaffirmed organic revenue decline of 0.5% to 1.5% and non-GAAP EPS of $10.80 to $11.30 (5% to 10% growth over 2025).
• Operating Margin Improvement: Expected to expand by 120 to 150 basis points in 2026, with significant improvements anticipated in the second half of the year.
• Second Quarter Outlook: Anticipated sequential improvement in financial results, with earnings per share expected to increase by at least 30% from Q1.

4. Bad News, Challenges, or Points of Concern

• Organic Revenue Decline: The first quarter saw a 1.5% decline in organic revenue, attributed to lower demand in certain segments and timing issues with NHP shipments.
• Margin Pressures: The decline in operating margin was driven by higher costs related to stock compensation and NHP sourcing.
• Funding Environment: While biotech funding has improved, early-stage biotech clients remain cautious, impacting demand.
• Competitive Pressures: Increased outsourcing of early-stage work to lower-cost regions like China poses a potential risk to Charles River's market share.

5. Notable Q&A Insights

• Demand Environment: Management noted a cautious optimism regarding biotech funding and a rebound in proposal volumes, particularly from larger clients.
• AI in Drug Discovery: Birgit expressed excitement about AI's potential but acknowledged that its impact on drug development is still in early stages.
• Client Engagement: There is a noted acceleration in the conversion of proposals to bookings, indicating improved client engagement and decision-making speed.
• Market Dynamics: The company is closely monitoring the competitive landscape in Asia, particularly regarding outsourcing trends and the potential for in-licensing programs from China.

This summary encapsulates the key points from the earnings call, highlighting both the positive developments and the challenges faced by Charles River Laboratories in Q1 2026.